United States Patent 7,838,558: Adapalene 0.3% Composition Claims, Expiration, Litigation, and Generic Risk

United States Patent 7,838,558 protects selected topical pharmaceutical compositions containing 0.3% adapalene, particularly aqueous carbomer gels in which adapalene is the sole anti-acne ingredient. The broad commercial relevance is Differin Gel 0.3%, marketed by Galderma. The strongest claims are composition claims 1, 5, and 15, while claims 4, 7, and 10 provide narrower protection for specified formulations.

The patent was issued on November 23, 2010, and is listed by the FDA for Differin Gel 0.3%. Public Orange Book data identify June 19, 2026, as the listed patent expiration date for the relevant adapalene 0.3% protection.[1] The patent does not protect every adapalene product. Its principal limitations are concentration, topical dosage form, acne treatment utility, and the requirement that adapalene be the only anti-acne ingredient in covered compositions.

What patents protect adapalene 0.3% products?

US 7,838,558 is directed to pharmaceutical compositions containing 0.3% adapalene by weight. The patent covers gels, creams, lotions, and certain other topical dosage forms, but the scope varies substantially by claim.

Item	Patent detail
Patent	US 7,838,558 B2
Subject	Topical pharmaceutical compositions containing adapalene
Active ingredient	6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid, adapalene
Concentration	0.3% by weight, equivalent to 3 mg/g
Principal indication	Acne treatment
Key dosage forms	Aqueous gel, cream, polyethylene glycol-based alcoholic lotion
Key formulation limitation	Adapalene is the sole anti-acne ingredient
Key gel limitation	Aqueous gel containing at least one carbomer gelling agent
Issue date	November 23, 2010
Listed expiration	June 19, 2026
Commercial product association	Differin Gel 0.3%
Patent holder or commercial sponsor	Galderma-related entities

The patent is a formulation and product-composition patent. It is not principally a patent on the chemical identity of adapalene itself. Earlier adapalene compound and use patents addressed the active pharmaceutical ingredient and its dermatological applications. Those earlier rights do not necessarily block a 0.3% product today because their terms generally expired before the period covered by US 7,838,558.

What does claim 1 of US 7,838,558 cover?

Claim 1 covers a topical pharmaceutical composition containing:

0.3% by weight adapalene or a pharmaceutically acceptable salt;
a pharmaceutically acceptable topical medium;
effectiveness for acne treatment; and
a limitation that, if the product is a gel, the gel is aqueous and contains at least one carbomer gelling agent.

The claim also requires that the sole anti-acne ingredient be adapalene when the composition is formulated as a gel. The claim is broad as to the non-active vehicle, subject to the gel-specific carbomer and aqueous-medium restrictions.

A product would generally fall within claim 1 if it contains 3 mg adapalene per gram, is intended to treat acne, and uses an aqueous carbomer gel vehicle without another anti-acne active. A product can avoid literal infringement if it contains a different adapalene concentration, uses a nonaqueous gel, or includes another anti-acne active, although the legal effect depends on the complete formulation and claim construction.

The phrase “sole anti-acne ingredient” is narrower than “sole active ingredient.” A covered product may contain preservatives, humectants, emulsifiers, pH adjusters, stabilizers, and other excipients. Those ingredients do not ordinarily become anti-acne ingredients merely because they have a supporting role in the formulation.

How do claims 2 through 4 narrow the patent scope?

Claims 2 through 4 depend on claim 1 and therefore retain all of claim 1’s limitations.

Claim 2: gel, cream, or lotion

Claim 2 identifies three dosage forms:

Topical aqueous gel;
Cream; and
Lotion.

For a gel, the claim 1 carbomer and aqueous-gel requirements remain relevant. The claim does not independently broaden the gel category beyond claim 1.

Claim 3: broad topical dosage-form list

Claim 3 lists:

Ointment;
Cream;
Milk;
Pomade;
Powder;
Impregnated pad;
Solution;
Aqueous gel;
Spray;
Lotion;
Patch;
Hydrogel; and
Lipid or polymeric microsphere or nanosphere suspension.

This claim is textually broad in dosage-form coverage, but it depends on claim 1. The claim therefore does not remove the 0.3% adapalene, acne-treatment, topical-medium, or sole-anti-acne-ingredient requirements. For gels, the aqueous-carbomer limitation from claim 1 remains material.

Claim 4: specified aqueous gel

Claim 4 covers a composition consisting essentially of an aqueous gel containing:

Adapalene;
Carbomer 940;
Disodium edetate;
Methyl paraben;
Poloxamer 124;
Propylene glycol;
Sodium hydroxide; and
Purified water.

“Consisting essentially of” permits components that do not materially affect the basic and novel characteristics of the composition. It is narrower than “comprising” and creates potential infringement disputes over additional excipients, substitutions, or formulation changes.

What do claims 5 through 7 protect?

Claims 5 through 7 focus on a 0.3% adapalene aqueous gel containing a carbomer and no other anti-acne ingredient.

Claim 5 is an independent composition claim. It requires:

0.3% adapalene;
An aqueous gel;
At least one carbomer gelling agent;
Acne-treatment effectiveness; and
Adapalene as the sole anti-acne ingredient.

Claim 6 narrows claim 5 to a composition containing carbomer 940 and/or propylene glycol. Claim 7 narrows the claim further to a specific formula.

The claim 7 formula contains 3 mg adapalene per gram and specifies the following approximate quantities:

Ingredient	Amount per gram
Adapalene	3 mg
Carbomer 940	11 mg
Disodium edetate	1 mg
Methyl paraben	2 mg
Poloxamer 124	2 mg
Propylene glycol	40 mg
Sodium hydroxide	Quantity sufficient for pH 5.0 ± 0.3
Purified water	Quantity sufficient to 1 g

The reference to Carbopol 980 in the claim text creates a potential nomenclature issue because Carbopol grades and carbomer compendial designations are not always interchangeable. A formulation dispute would likely turn on the actual polymer identity, grade, molecular characteristics, and whether the accused product satisfies the claim’s carbomer limitation.

What do claims 8 through 10 protect?

Claims 8 through 10 cover a 0.3% adapalene cream in which adapalene is the only anti-acne ingredient.

Claim 8 is the independent cream claim. Unlike claims 5 and 15, it does not require a carbomer or an aqueous gel. Claim 9 narrows the cream by requiring one or more selected ingredients:

Perhydrosqualene;
Cyclomethicone;
PEG-20 methyl glucose sesquistearate; or
Methyl glucose sesquistearate.

Claim 10 recites a detailed cream formulation:

Ingredient	Amount per gram
Adapalene	3 mg
Carbomer 934	4.5 mg
Disodium edetate	1 mg
PEG-20 methyl glucose sesquistearate	35 mg
Methyl glucose sesquistearate	35 mg
Glycerol	30 mg
Methyl paraben	2 mg
Cyclomethicone	130 mg
Perhydrosqualene	60 mg
Phenoxyethanol	5 mg
Propyl paraben	1 mg
Sodium hydroxide	Quantity sufficient for pH 6.5 ± 0.3
Purified water	Quantity sufficient to 1 g

The cream claims are commercially relevant to non-gel 0.3% adapalene products. A competitor using an emulsion with a different excipient system may avoid claims 9 and 10 while still requiring analysis under claim 8.

What does claim 11 cover for lotion products?

Claim 11 covers a 0.3% adapalene polyethylene glycol-based alcoholic lotion. It requires:

0.3% adapalene;
A topical pharmaceutically acceptable medium;
A polyethylene glycol-based alcoholic lotion;
Acne-treatment effectiveness; and
Adapalene as the sole anti-acne ingredient.

This claim is narrower than the broad topical composition claims because the vehicle must be both polyethylene glycol-based and alcoholic. A water-based lotion, oil-based lotion, or lotion using a different principal solvent system may fall outside claim 11, although the product could still implicate other claims depending on its composition.

What do claims 12 through 15 add?

Claims 12 through 14 permit specified inert additives in compositions covered by the gel, cream, and lotion claim groups. The listed categories include:

Wetting agents;
Preservatives;
Stabilizers;
Moisture regulators;
pH regulators;
Osmotic-pressure modifiers;
Emulsifiers;
UV-A and UV-B screening agents; and
Antioxidants.

These claims do not eliminate the underlying dosage-form and active-ingredient limitations. They protect the addition of excipients and formulation aids that are not themselves anti-acne actives.

Claim 15 is an independent aqueous-gel claim that overlaps materially with claims 1 and 5. It requires:

0.3% adapalene;
Adapalene as the only active anti-acne ingredient;
An aqueous gel;
At least one carbomer gelling agent; and
A topical pharmaceutical medium.

Because claims 1, 5, and 15 recite similar subject matter, invalidity or claim-construction arguments affecting the core 0.3% carbomer-gel concept could affect several independent claims at once. A defendant may still challenge individual claims separately based on anticipation, obviousness, written description, enablement, or indefiniteness.

When does US Patent 7,838,558 lose exclusivity?

The listed expiration date is June 19, 2026.[1] The effective market date may differ by product and regulatory pathway because FDA exclusivity, pediatric extensions, litigation stays, settlements, and other Orange Book patents can affect generic launch timing.

Milestone	Date or status
Patent issued	November 23, 2010
FDA-listed patent	US 7,838,558
Listed patent expiration	June 19, 2026
FDA product	Differin Gel 0.3%
Regulatory category	Prescription topical drug product
Post-expiration risk	Generic 0.3% adapalene gel and other covered formulations

The patent’s expiration does not create freedom to market every adapalene dosage form if separate patents, trademarks, regulatory exclusivity, or formulation rights apply. It removes the statutory exclusionary term of this patent, subject to any legally applicable adjustment or extension reflected in official records.

What is the Orange Book status of Differin Gel 0.3%?

The FDA Orange Book lists US 7,838,558 for Differin Gel 0.3%, an adapalene topical product associated with Galderma.[1] Orange Book listing is commercially important because an abbreviated new drug application applicant must address listed patents through a certification under 21 U.S.C. § 355(j)(2)(A)(vii), including a Paragraph IV certification when asserting that a listed patent is invalid, unenforceable, or will not be infringed.[2]

A Paragraph IV certification can lead to patent litigation under 35 U.S.C. § 271(e)(2). A timely infringement suit can trigger an FDA approval stay of up to 30 months, subject to statutory exceptions and court action.[2] The Orange Book listing itself does not establish that the patent is valid or infringed.

Which companies are challenging adapalene 0.3% patent rights?

Public regulatory records show generic activity for adapalene 0.3% gel, including ANDA approvals and abbreviated applications associated with generic manufacturers. The principal competitive issue is whether a generic applicant can:

Wait for patent expiration;
File a Paragraph III certification;
File a Paragraph IV certification;
Avoid the listed claims through a noninfringing formulation; or
Use a different dosage form or concentration.

Available public records do not establish a single comprehensive list of all Paragraph IV filers or all confidential settlement terms. Generic manufacturers have commercial incentives to challenge the patent because the product has a relatively simple active ingredient, a nonsterile topical manufacturing process, and a clear concentration target. The principal technical barrier is reproducing or substituting the gel system while avoiding the aqueous-carbomer and sole-anti-acne limitations.

What patent litigation affects US 7,838,558?

The statutory framework makes US 7,838,558 an ANDA litigation asset rather than a patent that ordinarily creates broad blocking rights across all adapalene products. The key litigation questions are likely to be:

Whether the accused product contains exactly 0.3% adapalene by weight;
Whether the product is an aqueous gel;
Whether the gelling agent is a carbomer;
Whether adapalene is the only anti-acne ingredient;
Whether the product is effective for acne treatment;
Whether a formulation change avoids a dependent claim; and
Whether the patent is valid over earlier adapalene compositions and dermatological formulations.

A generic applicant may contest the patent under Paragraph IV while designing around claim 7’s exact formula. Exact-ingredient claims such as claim 7 and claim 10 are easier to design around than claims 5 and 15, which focus on functional formulation architecture.

No publicly established settlement term should be inferred from an ANDA filing alone. A settlement may permit an authorized generic, delayed entry, or launch before patent expiration, but its existence and terms require a specific court docket or regulatory record.

How strong is the patent estate for adapalene 0.3%?

The patent estate is strongest against a conventional 0.3% aqueous carbomer gel with adapalene as the sole acne active. It is weaker against products that alter concentration, dosage form, vehicle chemistry, or active-ingredient combination.

Product design	Exposure under US 7,838,558
0.3% adapalene aqueous carbomer gel	High
0.3% adapalene gel with another acne active	Reduced under sole-active limitations
0.1% adapalene gel	Outside the 0.3% limitation
0.3% adapalene nonaqueous gel	Potentially outside gel claims requiring aqueous gel
0.3% adapalene cream	Potentially covered by claim 8
0.3% adapalene cream with listed excipients	Greater exposure under claims 9 and 10
0.3% adapalene PEG-based alcoholic lotion	Potential exposure under claim 11
Adapalene oral product	Outside the topical-composition claims
Adapalene combined with benzoyl peroxide	Potentially outside sole-anti-acne-ingredient claims

The patent has meaningful claim redundancy through multiple independent claims. That redundancy improves enforcement coverage but does not cure a fundamental validity problem. The core risk remains concentrated in a commercially standard product configuration rather than the entire adapalene market.

What manufacturing and formulation barriers exist after patent expiration?

The manufacturing process for adapalene gel is less complex than that for sterile injectables or biologics. The principal barriers are formulation quality and regulatory equivalence.

A generic applicant must control:

Adapalene content uniformity;
Particle size and dispersion;
Carbomer hydration and neutralization;
pH;
Viscosity and spreadability;
Microbial limits and preservative performance;
Packaging compatibility;
Stability under commercial storage; and
Topical bioequivalence or other FDA-required comparative data.

FDA’s topical-product guidance treats formulation, microstructure, rheology, and performance as potentially relevant to pharmaceutical equivalence and bioequivalence.[3] A generic manufacturer may avoid the patent while still facing FDA development costs, scale-up issues, and substitutability questions.

How does US 7,838,558 compare with adapalene 0.1% protection?

Adapalene 0.1% products, including the original Differin products, are not within the literal 0.3% concentration requirement of US 7,838,558. The 0.1% market also has a different regulatory and commercial history, including FDA approval of adapalene 0.1% for over-the-counter use in the United States.[4]

Attribute	Adapalene 0.1%	Adapalene 0.3%
Concentration	1 mg/g	3 mg/g
Representative product	Differin Gel 0.1%	Differin Gel 0.3%
Patent relevance	Earlier compound and formulation rights	US 7,838,558 composition rights
FDA status	OTC adapalene 0.1% approved	Prescription 0.3% product historically marketed
Primary commercial issue	Brand/generic OTC competition	Prescription generic entry and patent timing
Key claim risk under 7,838,558	Generally outside concentration limitation	Highest for aqueous carbomer gels

What is the revenue exposure from generic entry?

The revenue exposure is concentrated in the 0.3% prescription product and any related products using covered formulation concepts. Generic entry can reduce net pricing through:

Multiple ANDA approvals;
Pharmacy substitution;
Reimbursement pressure;
Formularies favoring lower-cost products; and
Channel migration from branded prescription products.

The patent does not block lower-strength adapalene products, combination acne products, or all topical retinoids. Revenue exposure therefore depends on the share of the sponsor’s dermatology portfolio attributable specifically to Differin Gel 0.3% and on whether the sponsor has later-generation products with separate patent protection.

Licensing and settlement exposure

Patent assignments and licenses can change the entity entitled to sue or receive royalties. Commercial records identify Galderma-related entities as the principal rights holders or sponsors associated with Differin. A licensing deal should be analyzed through USPTO assignment records, FDA sponsorship records, SEC disclosures where applicable, and litigation settlements. A generic settlement can materially change launch timing without changing the patent’s nominal expiration date.

Key Takeaways

US 7,838,558 is a formulation patent focused on 0.3% topical adapalene products.
Its highest-value claims cover aqueous carbomer gels in which adapalene is the sole anti-acne ingredient.
Claims 1, 5, and 15 are the principal independent gel claims.
Claim 8 covers 0.3% adapalene creams, while claim 11 covers a polyethylene glycol-based alcoholic lotion.
Claims 4, 7, and 10 protect narrower ingredient-defined formulations.
The FDA-listed expiration date is June 19, 2026.
A Paragraph IV challenge can trigger ANDA litigation and potentially a 30-month FDA approval stay.
The patent is weaker against 0.1% products, nonaqueous gels, combination acne products, and materially different vehicles.
Generic entry risk is highest for a conventional 0.3% aqueous carbomer gel that uses adapalene as its only anti-acne active.
Patent expiration does not eliminate separate regulatory, trademark, formulation, or later-filed patent risks.

FAQs

Can a generic launch a 0.3% adapalene gel before June 19, 2026?

Only if it obtains a lawful early-entry pathway, such as a successful Paragraph IV challenge, a settlement-authorized launch, or another outcome that removes the patent-based barrier.

Does adding benzoyl peroxide avoid US 7,838,558?

It may avoid claims requiring adapalene to be the sole anti-acne ingredient, but the complete formulation must be compared with every asserted claim. Other patents may cover the combination.

Does changing Carbopol 980 to another carbomer avoid infringement?

Not necessarily. The broad gel claims require at least one carbomer, while the narrow formulation claims identify particular carbomer grades or compositions. The precise polymer and claim construction control.

Does US 7,838,558 cover adapalene foam?

The listed claims do not expressly recite foam. A foam product would require analysis under the broader dosage-form language and any applicable equivalents doctrine, as well as separate patents directed to foam formulations.

Is adapalene 0.1% protected by this patent?

A 0.1% product does not meet the express 0.3% by-weight limitation in the claims of US 7,838,558. Separate patents, trademarks, regulatory requirements, or other rights may still apply.

References

U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: Refuse-to-receive standards. FDA.
U.S. Food and Drug Administration. (2022). Development of topical dermatologic drug products for treatment of acne vulgaris: Guidance for industry. FDA.
U.S. Food and Drug Administration. (2016). FDA approves first over-the-counter adapalene gel to treat acne. FDA.
United States Patent and Trademark Office. (2010). U.S. Patent No. 7,838,558, Pharmaceutical compositions containing adapalene. USPTO.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
France	02 03070	Mar 12, 2002

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	038924	⤷ Start Trial
Austria	417610	⤷ Start Trial
Austria	432072	⤷ Start Trial
Australia	2003216898	⤷ Start Trial
Australia	2008203279	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,838,558

Summary for Patent: 7,838,558